Phio Pharmaceuticals says it reached an important step for its drug PH-762 and is moving forward with FDA plans.

Sep 14, 2026, 9:08 AM ETTrialRead the original at sec.gov

Good for PHIO

Phio Pharmaceuticals filed an 8-K saying it submitted materials to the FDA for PH-762 and plans a Phase 2b neoadjuvant study; this advances its clinical program.

PHIO · Phio Pharmaceuticals Corp.

AI read · Good for PHIO

The AI's read

Phio filed an 8-K saying it submitted materials to the FDA for PH-762 and plans a Phase 2b nesect study. That advances the drug's clinical program and is a direct positive for development.

Get alerts for PHIO

Follow Phio Pharmaceuticals Corp. (PHIO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PHIO

Free on the App Store and Google Play, or on the web.